Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1583f1afe5a54ea596b4387156690961 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1583f1afe5a54ea596b4387156690961 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1583f1afe5a54ea596b43871566909612021-11-14T08:30:04ZBurosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension10.1136/rmdopen-2021-0017142056-5933https://doaj.org/article/1583f1afe5a54ea596b43871566909612021-11-01T00:00:00Zhttps://rmdopen.bmj.com/content/7/3/e001714.fullhttps://doaj.org/toc/2056-5933Karine BriotRachel K CrowleyMaria Luisa BrandiStuart H RalstonHan-Wook YooPeter KamenickýTakuo KubotaNobuaki ItoMartine Cohen-SolalRichard KeenAngela WilliamsMuhammad K JavaidHiroyuki TanakaRobin H LachmannKarl InsognaRichard EastellYasuhiro TakeuchiAnthony A PortaleThomas O CarpenterHae Ii CheongYasuo ImanishiSteven IngSuzanne Jan de BeurFarzana PerwadPisit PitukcheewanontThomas J WeberAnnabel NixonMark NixonErik A ImelBMJ Publishing GrouparticleMedicineRENRMD Open, Vol 7, Iss 3 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R |
| spellingShingle |
Medicine R Karine Briot Rachel K Crowley Maria Luisa Brandi Stuart H Ralston Han-Wook Yoo Peter Kamenický Takuo Kubota Nobuaki Ito Martine Cohen-Solal Richard Keen Angela Williams Muhammad K Javaid Hiroyuki Tanaka Robin H Lachmann Karl Insogna Richard Eastell Yasuhiro Takeuchi Anthony A Portale Thomas O Carpenter Hae Ii Cheong Yasuo Imanishi Steven Ing Suzanne Jan de Beur Farzana Perwad Pisit Pitukcheewanont Thomas J Weber Annabel Nixon Mark Nixon Erik A Imel Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension |
| format |
article |
| author |
Karine Briot Rachel K Crowley Maria Luisa Brandi Stuart H Ralston Han-Wook Yoo Peter Kamenický Takuo Kubota Nobuaki Ito Martine Cohen-Solal Richard Keen Angela Williams Muhammad K Javaid Hiroyuki Tanaka Robin H Lachmann Karl Insogna Richard Eastell Yasuhiro Takeuchi Anthony A Portale Thomas O Carpenter Hae Ii Cheong Yasuo Imanishi Steven Ing Suzanne Jan de Beur Farzana Perwad Pisit Pitukcheewanont Thomas J Weber Annabel Nixon Mark Nixon Erik A Imel |
| author_facet |
Karine Briot Rachel K Crowley Maria Luisa Brandi Stuart H Ralston Han-Wook Yoo Peter Kamenický Takuo Kubota Nobuaki Ito Martine Cohen-Solal Richard Keen Angela Williams Muhammad K Javaid Hiroyuki Tanaka Robin H Lachmann Karl Insogna Richard Eastell Yasuhiro Takeuchi Anthony A Portale Thomas O Carpenter Hae Ii Cheong Yasuo Imanishi Steven Ing Suzanne Jan de Beur Farzana Perwad Pisit Pitukcheewanont Thomas J Weber Annabel Nixon Mark Nixon Erik A Imel |
| author_sort |
Karine Briot |
| title |
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension |
| title_short |
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension |
| title_full |
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension |
| title_fullStr |
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension |
| title_full_unstemmed |
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension |
| title_sort |
burosumab treatment in adults with x-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension |
| publisher |
BMJ Publishing Group |
| publishDate |
2021 |
| url |
https://doaj.org/article/1583f1afe5a54ea596b4387156690961 |
| work_keys_str_mv |
AT karinebriot burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT rachelkcrowley burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT marialuisabrandi burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT stuarthralston burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT hanwookyoo burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT peterkamenicky burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT takuokubota burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT nobuakiito burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT martinecohensolal burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT richardkeen burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT angelawilliams burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT muhammadkjavaid burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT hiroyukitanaka burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT robinhlachmann burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT karlinsogna burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT richardeastell burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT yasuhirotakeuchi burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT anthonyaportale burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT thomasocarpenter burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT haeiicheong burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT yasuoimanishi burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT stevening burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT suzannejandebeur burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT farzanaperwad burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT pisitpitukcheewanont burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT thomasjweber burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT annabelnixon burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT marknixon burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension AT erikaimel burosumabtreatmentinadultswithxlinkedhypophosphataemia96weekpatientreportedoutcomesandambulatoryfunctionfromarandomisedphase3trialandopenlabelextension |
| _version_ |
1718429760524124160 |